Table 3.
Dose levels (DLs) and dose-limiting toxicities (DLTs)
| DL | Patients | Cisplatin (mg/m2) | Pazopanib (mg/day) | DL escalating order | DLT | Description |
|---|---|---|---|---|---|---|
| −2 | 3 + 1NEa | 75 | 200 | 3 | 0 | |
| −1 | 3 | 60 | 400 | 2 | 0 | |
| 1 | 3 + 3NEa | 75 | 400 | 1 | 1 | One patient with G3 ALT elevation and G3 pulmonary embolism |
| 3 + 2NEa | 4 | |||||
| 2 | 6 | |||||
| 2 | 5 + 1NEa | 75 | 600 | 5 | 3 | Two patients with G3 thrombocytopenia + G3 neutropeniab |
| One patient with G4 hyponatremia + G3 ALT elevation | ||||||
| 1 RS | 9 | 75 | 400 | 7 | 1 | One patient with G3 pulmonary embolism |
G grade, ALT alanine aminotransferase, RS reverse sequence
aNon evaluable for DLT
bResulting in >2 weeks delay in C2 cisplatin administration